Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Intelligent Systems (INS) -- Ignore unavailable to you. Want to Upgrade?

To: architect* who wrote (8)	3/13/2000 1:40:00 AM
From: architect*	Read Replies (1) \| Respond to of 25

AtheroGenics Files with the Securities and Exchange Commission for an Initial Public Offering of Common Stock ATLANTA, GA (February, 28, 2000)?AtheroGenics, Inc., an Alpharetta-based pharmaceutical company, announced today that it has filed with the Securities and Exchange Commission for an initial public offering of its common stock. The offering will be managed by SG Cowen Securities Corporation, Chase H&Q, Adams Harkness & Hill, Inc. and A.G. Edwards & Sons, Inc. The Company expects to have its shares traded on the Nasdaq National Market under the symbol 'AGIX'. AtheroGenics commenced operations in 1994 and is focused on the discovery, development and commercialization of novel small molecule therapeutics for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. Based on a proprietary drug discovery technology platform called vascular protectant, or v-protectant, technology, the Company designed its lead product candidate, AGI-1067, to benefit patients with coronary artery disease, which is atherosclerosis of the blood vessels of the heart. In addition to AGI-1067, the Company is developing new v-protectants for the treatment of asthma, cystic fibrosis, rheumatoid arthritis and solid organ transplant rejection. A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these shares in any state or other jurisdiction, in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering will be made only by means of a Prospectus. Prospectuses, subject to completion, relating to these securities are expected to be available in April 2000 from SG Cowen, 1221 Avenue of the Americas, 14th Floor, New York, New York 10020.